US FDA May Grant More Emergency Use Authorizations For COVID-19 Treatments This Fall
Convalescent plasma, anti-inflammatory agents among those that could be considered for EUAs, Commissioner Hahn says during congressional hearing on the coronavirus response.
You may also be interested in...
Commissioner Stephen Hahn was largely spared any direct criticism during a very long House hearing on COVID-19 response activities. That is a promising sign for the agency.
Commissioner says the agency is reviewing efficacy and safety data, presumably for an emergency use authorization of a product derived from patients who recovered from the virus.
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.